Corvus Pharmaceuticals CRVS Deferred Tax Assets and Other Non-Current Assets
Deferred Tax Assets and Other Non-Current Assets at other companies
Other financials
Where this comes from
Reported directly by Corvus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.
The official record: Corvus Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Corvus Pharmaceuticals's deferred tax assets and other non-current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Corvus Pharmaceuticals's deferred tax assets and other non-current assets?
- Corvus Pharmaceuticals (CRVS) reported deferred tax assets and other non-current assets of $1.72M in Q1 2026.
- How has Corvus Pharmaceuticals's deferred tax assets and other non-current assets changed year-over-year?
- Corvus Pharmaceuticals's deferred tax assets and other non-current assets increased by 173.4% year-over-year, from $629K to $1.72M.
- What is the long-term trend for Corvus Pharmaceuticals's deferred tax assets and other non-current assets?
- Over 5 years (2020 to 2025), Corvus Pharmaceuticals's deferred tax assets and other non-current assets has grown at a 15.6% compound annual growth rate (CAGR), from $414K to $855K.